IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i13p8211-d855953.html
   My bibliography  Save this article

Metformin and the Development of Asthma in Patients with Type 2 Diabetes

Author

Listed:
  • Fu-Shun Yen

    (Dr. Yen’s Clinic, Taoyuan 33354, Taiwan)

  • Chih-Cheng Hsu

    (Institute of Population Health Sciences, National Health Research Institutes, Miaoli County 35053, Taiwan
    Department of Health Services Administration, China Medical University, Taichung 40402, Taiwan
    Department of Family Medicine, Min-Sheng General Hospital, Taoyuan 33044, Taiwan)

  • Ying-Hsiu Shih

    (Management Office for Health Data, China Medical University Hospital, Taichung 40459, Taiwan
    College of Medicine, China Medical University, Taichung 40201, Taiwan)

  • Wei-Lin Pan

    (Department of Internal Medicine, Mackay Memorial Hospital, Taipei 10449, Taiwan)

  • James Cheng-Chung Wei

    (Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
    Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
    Graduate Institute of Integrated Medicine, China Medical University, Taichung 40402, Taiwan)

  • Chii-Min Hwu

    (Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei 11221, Taiwan
    Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan)

Abstract

We conducted this study to compare the risks of asthma development and exacerbation between metformin users and nonusers. Overall, 57,743 propensity score-matched metformin users and nonusers were identified from Taiwan’s National Health Insurance Research Database between 1 January 2000, and 31 December 2017. We used the Cox proportional hazards model with robust standard error estimates to compare the risks of asthma onset, exacerbation, and hospitalization for asthma in participants with type 2 diabetes (T2D). Compared with metformin nonuse, the aHRs (95% CI) for metformin use in asthma development, exacerbation, and hospitalization for asthma were 1.13 (1.06–1.2), 1.62 (1.35–1.95), and 1.5 (1.22–1.85), respectively. The cumulative incidences of asthma development, exacerbation, and hospitalization for asthma were significantly higher in metformin users than nonusers ( p < 0.001). A longer cumulative duration of metformin use for more than 728 days was associated with significantly higher risks of outcomes than metformin nonuse. Our study demonstrated that metformin users showed significantly higher risks of asthma development, exacerbation, and hospitalization for asthma than metformin nonusers. Moreover, metformin use for more than 728 days was associated with higher risks of outcomes. A randomized control study is warranted to verify our results.

Suggested Citation

  • Fu-Shun Yen & Chih-Cheng Hsu & Ying-Hsiu Shih & Wei-Lin Pan & James Cheng-Chung Wei & Chii-Min Hwu, 2022. "Metformin and the Development of Asthma in Patients with Type 2 Diabetes," IJERPH, MDPI, vol. 19(13), pages 1-13, July.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:13:p:8211-:d:855953
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/13/8211/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/13/8211/
    Download Restriction: no
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Fu-Shun Yen & Chih-Cheng Hsu & Kai-Chieh Hu & Yu-Tung Hung & Chung Y. Hsu & James Cheng-Chung Wei & Chii-Min Hwu, 2022. "Metformin and the Risk of Chronic Urticaria in Patients with Type 2 Diabetes," IJERPH, MDPI, vol. 19(17), pages 1-12, September.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:13:p:8211-:d:855953. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.